High density lipoprotein landmark trials: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
Line 31: | Line 31: | ||
| [[Dal-VESSEL Trial]] | | [[Dal-VESSEL Trial]] | ||
|- | |- | ||
| [[Dal-PLAQUE]] | | [[Dal-PLAQUE Trial]] | ||
|- | |- | ||
| [[ILLUMINATE Trial]] | | [[ILLUMINATE Trial]] |
Revision as of 01:22, 20 September 2013
High Density Lipoprotein Microchapters |
Diagnosis |
---|
Treatment |
Clinical Trials |
Case Studies |
High density lipoprotein landmark trials On the Web |
American Roentgen Ray Society Images of High density lipoprotein landmark trials |
Risk calculators and risk factors for High density lipoprotein landmark trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Reconstituted HDL Infusion
CETP Inhibitors
ACCELERATE Trial |
Dal-OUTCOMES Trial |
DEFINE Trial |
Dal-VESSEL Trial |
Dal-PLAQUE Trial |
ILLUMINATE Trial |
ILLUSTRATE Trial |
REVEAL Trial |
Niacin
AIM-HIGH Trial |
ARBITER 2 Trial |
ARBITER 3 Trial |
ARBITER 6-HALTS Trial |
CLAS Trial |
HATS Trial |
Oxford Niaspan Study |
Fibrate
VA-HIT Trial |
BECAIT Trial |
BIP Trial |
Statin
ASTEROID Trial |
SATURN Trial |
4S Trial |
CORONA Trial |
Multiple Lipid Lowering Drugs
HARP Study |
AFREGS Trial |